September 27, 2019
Tmunity Announces Presentation at the Cantor Fitzgerald 2019 Global Healthcare Conference
PHILADELPHIA, PA, September 27, 2019 – Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Christina Coughlin, MD, PhD, Executive Vice President and Chief Medical Officer, and members of the management team plan to participate at the Cantor Fitzgerald 2019 Global Healthcare Conference in New York City on October 3, 2019. The company will webcast a presentation on Tmunity at 4:45 p.m. ET.
About Tmunity Therapeutics
Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.
# # #
Lisa A. Hayes
VP, Investor Relations and Corporate Communications
Mike Beyer, Sam Brown Inc.